Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Interventions for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels

NCT04931420 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT04931420
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04931420 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Interventions for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
Lead sponsor
University of Chicago
Phase
Phase 2
Overall status
Withdrawn
Start date
May 19, 2022
Completion date
November 1, 2027
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

foregut carcinoid tumor, gallbladder adenocarcinoma, gastric adenocarcinoma, gi cancer, gi carcinoma, liver cancer, lung cancer, metastatic cancer